- The stock price of NanoVibronix Inc NAOV closed 250% higher at $2.61 in very volatile and active afternoon trading Friday, and the stock is up almost 31% at $3.41 during the premarket on Monday.
- Investors appear to be reacting after the Company announced on Thursday that The Journal of Medical & Surgical Urology is publishing an article with overwhelmingly positive findings from a study of patients that used its UroShield in real-world settings.
- For the study, 23 patients with reoccurring urinary tract infections (UTIs) were offered for using the UroShield device for a minimum period of 12 weeks.
- As part of the findings, patients reported a significant decrease in the number of UTIs and antibiotic treatment, had fewer catheter blockages and catheter changes, and the pain was reduced significantly by the end of the study.
- Adding to the compelling data, the device also scored approval in Australia.
- Price Action: NAOV shares are up 30.6% at $3.41 during the premarket session on the last check Monday.
- Related content: Benzinga's Full FDA Calendar.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...